Cyanotech CORP Form 4 insider transactions

Cyanotech's CFO, Jennifer Miyashiro, was granted 50,000 stock options with an exercise price of $0.29, vesting over three years.

Cyanotech Corporation Director David M. Mulder acquired 50,000 shares of common stock, increasing his beneficial ownership to 203,468 shares.

Cyanotech Corp. Director David L. Vied is set to acquire 50,000 common shares on August 28, 2025, under a Rule 10b5-1 plan.

A Cyanotech Corporation director and 10% owner, Michael A. Davis, plans to acquire 50,000 shares of common stock on August 28, 2025, under a Rule 10b5-1 plan.

Cyanotech Corp's President and CEO, Matthew Keith Custer, acquired 2,075 shares of common stock through the vesting of restricted stock units, increasing his direct common stock holdings to 6,754 shares.

Amy Beth Nordin, VP, HR, and Secretary of Cyanotech Corporation, converted 1,502 restricted stock units into common stock and had 525 shares withheld for tax liabilities.

Jennifer M. Johansen, VP of Quality, Regulatory & Government at Cyanotech Corp, converted 1,380 restricted stock units into common stock, with 518 shares withheld by the company to cover payroll tax liabilities.

Cyanotech's Chief Scientific Officer, Gerald R. Cysewski, converted restricted stock units into common stock and had shares withheld for tax obligations.

Cyanotech Corp's VP of Operations, Glenn Jensen, converted restricted stock units into common stock and had shares withheld for tax liabilities, as detailed in a recent SEC Form 4 filing.

Cyanotech Corp. has granted its President and CEO, Matthew Keith Custer, a substantial equity compensation package comprising stock options and restricted stock units, effective June 16, 2025.

Jennifer Kimberly Brand, VP of Sales at Cyanotech Corp, reports the acquisition of 50,000 Cyanotech common stock options.

Amy Beth Nordin, VP, HR, and Secretary of Cyanotech Corp, reports the acquisition of 75,000 stock options.

Glenn Jensen, VP of Operations at Cyanotech Corp, reports the acquisition of 25,000 Cyanotech common stock options.

Collette Nicole Kakuk, Chief Strategic Commercial Officer of Cyanotech Corporation, reports the vesting of restricted stock units and subsequent withholding of shares for tax liabilities.

Amy Beth Nordin, VP, HR, and Secretary of Cyanotech Corp, reports the vesting of restricted stock units and withholding of shares for tax liabilities.

Jennifer M. Johansen, VP at Cyanotech Corp, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.

Glenn Jensen, VP of Operations at Cyanotech Corp, reports the vesting of restricted stock units and associated tax withholding.

President and CEO of Cyanotech Corp, Matthew Keith Custer, reports the conversion of restricted stock units into common stock.

Gerald R Cysewski, Chief Scientific Officer of Cyanotech Corp, reports changes in beneficial ownership of company stock due to vesting of restricted stock units and associated tax withholding.

Collette Nicole Kakuk, Chief Strategic Commercial Officer of Cyanotech Corporation, reports the vesting of restricted stock units and subsequent withholding of shares for tax liabilities.

Amy Beth Nordin, VP, HR, and Secretary of Cyanotech Corp, converted restricted stock units into common stock and had shares withheld to cover payroll tax liability.

VP Jennifer M. Johansen reports the vesting of restricted stock units and subsequent withholding of shares for tax liabilities.

Glenn Jensen, VP of Operations at Cyanotech Corp, reports the vesting of restricted stock units and withholding of shares for tax liabilities.

Gerald R Cysewski, Chief Scientific Officer of Cyanotech Corp, reports the vesting of restricted stock units and subsequent withholding of shares for tax liabilities.

Director Michael Davis increased his holdings in Cyanotech through a stock plan and open market purchase.

Director Michael Davis increased his holdings in Cyanotech through purchases made under a 10b5-1 trading plan.

Director Michael Davis increased his holdings in Cyanotech through open market purchases executed under a pre-arranged 10b5-1 trading plan.

Director Michael Davis reports purchasing additional shares of Cyanotech Corp through a revocable trust.

Director Michael Davis has increased his stake in Cyanotech through purchases made under a 10b5-1(c) plan.

Director Michael Davis increased his indirect holdings in Cyanotech through purchases made via a revocable trust.